March 22, 2024Cancer Research

Efficacy of MDM2 and Epigenetic Inhibitors Against Pediatric Neuroblastoma Cells

View Full Paper

Ask AI

Bookmark

Authors

TMTahani MomenahSoutheastern University UNUmamaheswari NatarajanNova Southeastern University SJShyam JaganathanNova Southeastern University

Discussion

Member takes

Implication

In vitro study demonstrates cell death and tumor suppressor activation in neuroblastoma cell lines, highlighting epigenetic therapy as a potential treatment strategy.

Key Points

Robust cell death and growth arrest occur in neuroblastoma cells following exposure to targeted mdm2 inhibitor and epigenetic modifier therapies.
A 24-hour treatment with RG7388, CM272, and SAHA induced marked cell death while significantly elevating p53 and p21 expression levels in SK-N-SH cells.
Western blot analysis and luminescent viability assays measured apoptotic markers alongside altered dna methylation in treated neuroblastoma cell models.
Highlights therapeutic potential for combined epigenetic modifiers in pediatric neuroblastoma; however, findings rely on cell models and require in vivo validation.

Cite This Study

Momenah et al. (2024) studied this question.

synapsesocial.com/papers/68e72ce5b6db6435876a6dcd https://doi.org/10.1158/1538-7445.am2024-2865

View Full Paper

Ask AI

Bookmark

Implication

In vitro study demonstrates cell death and tumor suppressor activation in neuroblastoma cell lines, highlighting epigenetic therapy as a potential treatment strategy.

Efficacy of MDM2 and Epigenetic Inhibitors Against Pediatric Neuroblastoma Cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of MDM2 and Epigenetic Inhibitors Against Pediatric Neuroblastoma Cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider